Form 4: Pfizer Executive Vice President Sally Susman Reports Stock Transactions

Sally Susman, Executive Vice President of Pfizer, reports the earn-out and subsequent transactions related to stock appreciation rights.

Summary

• On February 27, 2025, Sally Susman, an Executive Vice President at Pfizer, engaged in transactions involving Pfizer common stock.
• These transactions included the earn-out of 85,182 stock appreciation rights at a price of $31.31.
• Susman also had shares withheld to satisfy tax obligations (2,178 shares at $26.1) and to cover the exercise price of the stock appreciation rights (79,779 shares at $26.06).
• Following these transactions, Susman directly owns 168,909 shares of Pfizer common stock and indirectly owns 866 shares through a Rule 16b-3 plan.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It is neutral in tone and does not convey any particularly positive or negative sentiment.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies like Pfizer.
• Companies such as Johnson & Johnson (JNJ) and Merck (MRK) also regularly report similar Form 4 filings for their executives.
• The details of these transactions, such as the number of shares and prices, are specific to the individual executive's compensation and stock option plans, making direct comparisons challenging without detailed knowledge of those plans.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect the executive's compensation and do not indicate a significant change in the company's financial position.

Key Dates